2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.02 Watson

PP01.02 Watson - Abstract

Pdf Summary

The study explores the impact of high-copy number gain (CNG) of ERBB2, KRAS, and MET on the tumor immune microenvironment (TME) and response to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). NSCLC with ERBB2 mutations exhibit limited benefits from ICI therapy, while KRAS and MET mutated cancers may respond better. The research analyzed 5870 lung adenocarcinomas to determine the influence of CNG of these oncogenes on TME markers and post-ICI survival. Results indicate that ERBB2 CNG-High tumors show lower positivity for pro-immune TME markers compared to KRAS or MET CNG-High tumors. Patients with ERBB2 CNG-High tumors had decreased survival post-ICI compared to CNG-Low tumors, while there was no significant difference observed for KRAS or MET amplification. This suggests that CNG of oncogenes in NSCLC may impact TME markers and survival post-ICI, with ERBB2 CNG-High status correlating with lower survival outcomes. Further investigation into the impact of CNG on ICI therapy in NSCLC is recommended.

Keywords

high-copy number gain

ERBB2

KRAS

MET

tumor immune microenvironment

immune checkpoint inhibitors

non-small cell lung cancer

oncogenes

TME markers

post-ICI survival